https://www.mel-montmedical.com/melmont_validations/view-our-last-mia-by-xytotest-clinical-study-publication-self-collected-versus-clinician-collected-cervical-samples-for-the-detection-of-hpv-infections-by-14-type-dna-and-7-type-mrna-tests-d/ 2021-06-03T16:43:36+00:00 https://www.mel-montmedical.com/melmont_validations/quality-control-of-cervical-cytology-using-a-3-type-hpv-mrna-test-increases-screening-program-sensitivity-of-cervical-intraepithelial-neoplasia-grade-2-in-young-norwegian-women-a-cohort-stud/ 2020-12-30T22:05:14+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/5-type-hpv-mrna-versus-14-type-hpv-dna-test-test-performance-over-diagnosis-and-overtreatment-in-triage-of-women-with-minor-cervical-lesions/ 2020-12-30T22:02:23+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/78080409_m.jpg https://www.mel-montmedical.com/melmont_validations/triage-of-women-with-minor-abnormal-cervical-cytology/ 2020-12-30T21:55:35+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/76563371_m.jpg https://www.mel-montmedical.com/melmont_validations/predictive-testing-of-early-cervical-pre-cancer-by-detecting-human-papillomavirus-e6-e7-mrna-in-cervical-cytologies-up-to-high-grade-squamous-intraepithelial-lesions-diagnostic-and-prognostic-implica/ 2020-12-30T21:52:51+00:00 https://www.mel-montmedical.com/melmont_validations/role-of-high-risk-human-papillomavirus-hpv-mrna-testing-in-the-prediction-of-residual-disease-after-conisation-for-high-grade-cervical-intraepithelial-neoplasia/ 2020-12-30T21:50:21+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/cytology-and-human-papillomavirus-testing-6-to-12-months-after-ascus-or-lsil-cytology-in-organized-screening-to-predict-highgrade-cervical-neoplasia-between-screening-rounds/ 2020-12-30T21:44:42+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/scientist-in-lab-P96ATWK.jpg https://www.mel-montmedical.com/melmont_validations/management-and-triage-of-women-with-human-papillomavirus-infection-in-follow-up-for-low-grade-cervical-disease-association-of-hpv-dna-and-rna-based-methods/ 2020-12-30T21:43:38+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/76563371_m.jpg https://www.mel-montmedical.com/melmont_validations/a-comparison-of-seven-tests-for-high-grade-cervical-intraepithelial-neoplasia-in-women-with-abnormal-smears-the-predictors-2-study/ 2020-12-30T21:41:09+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/discussing-cardiogram-4W244KN.jpg https://www.mel-montmedical.com/melmont_validations/comparison-of-predictors-for-high-grade-cervical-intraepithelial-neoplasia-in-women-with-abnormal-smears/ 2020-12-30T21:36:24+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/microbiologist-inspecting-petri-dish-observing-bac-U3CFBVN.jpg https://www.mel-montmedical.com/melmont_validations/management-of-low-grade-cervical-cytology-in-young-women-cohort-study-from-denmark/ 2020-12-30T21:31:58+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/primary-cervical-cancer-screening-with-an-hpv-mrna-test-a-prospective-cohort-study/ 2020-12-30T21:25:09+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/hpv-mrna-is-more-specific-than-hpv-dna-in-triage-of-women-with-minor-cervical-lesions/ 2020-12-30T21:22:13+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/scientist-in-lab-P96ATWK.jpg https://www.mel-montmedical.com/melmont_validations/hpv-mrna-testing-in-triage-of-women-with-asc-us-cytology-may-reduce-the-time-for-cin2-diagnosis-compared-with-repeat-cytology/ 2020-12-30T21:19:12+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/triage-of-women-with-low-grade-cervical-lesions-hpv-mrna-testing-versus-repeat-cytology/ 2020-12-30T21:16:32+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/unrecognizable-scientist-MDF3BQY.jpg https://www.mel-montmedical.com/melmont_validations/hpv-e6-e7-mrna-testing-is-more-specific-than-cytology-in-post-colposcopy-follow-up-of-women-with-negative-cervical-biopsy/ 2020-12-30T21:11:14+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/78080409_m.jpg https://www.mel-montmedical.com/melmont_validations/triage-of-women-with-minor-cervical-lesions-data-suggesting-a-test-and-treat-approach-for-hpv-e6-e7-mrna-testing/ 2020-12-30T21:07:18+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/prognostic-value-of-hpv-e6-e7-mrna-assay-in-women-with-negative-colposcopy-or-cin1-histology-result-a-follow-up-study/ 2020-12-30T21:03:38+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/78080409_m.jpg https://www.mel-montmedical.com/melmont_validations/1295/ 2020-12-30T20:59:10+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/triage-of-low%e2%80%90grade-squamous-intraepithelial-lesions-using-human-papillomavirus-messenger-ribonucleic-acid-tests-a-prospective-population%e2%80%90based-register-study/ 2020-12-30T20:49:56+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/scientist-hands-with-microscope-PUCV3KY.jpg https://www.mel-montmedical.com/melmont_validations/clinical-performance-of-the-pretect-hpv-proofer-e6-e7-mrna-assay-in-comparison-with-that-of-the-hybrid-capture-2-test-for-identification-of-women-at-risk-of-cervical-cancer/ 2020-12-30T20:44:01+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Image-1-RD.jpg https://www.mel-montmedical.com/melmont_validations/hpv-types-in-cervical-cancer-tissue-in-south-africa-a-head-to-head-comparison-by-mrna-and-dna-tests/ 2020-12-30T20:35:02+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/comparison-of-different-commercial-methods-for-hpv-detection-in-follow-up-cytology-after-ascus-lsil-prediction-of-cin2-3-in-follow-up-biopsies-and-spontaneous-regression-of-cin2-3/ 2020-12-30T20:23:48+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/doctor-female-background-beautiful-board-check-clipboard-document-file-folder-girl-isolated-lady-list_t20_nRb2A4.jpg https://www.mel-montmedical.com/melmont_validations/comparative-effectiveness-study-on-human-papillomavirus-detection-methods-used-in-the-cervical-cancer-screening-programme/ 2020-12-30T20:16:31+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/pretecttm-hpv-proofer-real-time-detection-and-typing-of-e6-e7-mrna-from-carcinogenic-human-papillomaviruses/ 2020-12-30T20:11:43+00:00 https://www.mel-montmedical.com/melmont_validations/predicting-cin2-when-detecting-hpv-mrna-and-dna-by-pretect-hpv-proofer-and-consensus-pcr-a-2-year-follow-up-of-women-with-ascus-or-lsil-pap-smear/ 2020-12-30T20:07:03+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/76563371_m.jpg https://www.mel-montmedical.com/melmont_validations/human-papillomavirus-e6-e7-mrna-expression-in-women-younger-than-30-years-of-age/ 2020-12-30T20:01:04+00:00 https://www.mel-montmedical.com/melmont_validations/comparison-of-human-papillomavirus-messenger-rna-and-dna-detection-a-cross-sectional-study-of-4136-women-30-years-of-age-with-a-2-year-follow-up-of-highgrade-squamous-intraepithelial-lesion/ 2020-12-30T19:46:51+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Image-1-RD.jpg https://www.mel-montmedical.com/melmont_validations/comparison-of-human-papillomavirus-testing-strategies-for-triage-of-women-referred-with-low-grade-cytological-abnormalities/ 2020-12-30T18:39:58+00:00 https://www.mel-montmedical.com/melmont_validations/dna-versus-rna-based-methods-for-human-papillomavirus-detection-in-cervical-neoplasia/ 2020-12-30T18:33:51+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Image-1-RD.jpg https://www.mel-montmedical.com/melmont_validations/presence-of-e6-and-e7-mrna-from-human-papillomavirus-types-16-18-31-33-and-45-in-the-majority-of-cervical-carcinomas/ 2020-12-30T18:27:17+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/78080409_m.jpg https://www.mel-montmedical.com/melmont_validations/human-papillomavirus-oncogenic-expression-in-the-dysplastic-portio-an-investigation-of-biopsies-from-190-cervical-cones/ 2020-12-30T17:01:20+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/the-majority-of-viral-cellular-fusion-transcripts-in-cervical-carcinomas-cotranscribe-cellular-sequences-of-known-or-predicted-genes/ 2020-12-30T16:55:03+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/78080409_m.jpg https://www.mel-montmedical.com/melmont_validations/comparison-of-hpv-detection-technologies-hybrid-capture-2-pretecttm-hpv-proofer-and-analysis-of-hpv-dna-viral-load-in-hpv16-hpv18-and-hpv33-e6-e7-mrna-positive-specimens/ 2020-12-30T16:48:52+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/microbiologist-inspecting-petri-dish-observing-bac-U3CFBVN.jpg https://www.mel-montmedical.com/melmont_validations/e6-e7-mrna-expression-analysis-a-test-for-the-objective-assessment-of-cervical-adenocarcinoma-in-clinical-prognostic-procedure/ 2020-12-30T16:37:40+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/a-comprehensive-evaluation-of-the-accuracy-of-cervical-pre-cancer-detection-methods-in-a-high-risk-area-in-east-congo/ 2020-12-30T16:32:14+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/microbiologist-inspecting-petri-dish-observing-bac-U3CFBVN.jpg https://www.mel-montmedical.com/melmont_validations/clinical-performance-anyplex-ii-hpv28/ 2020-12-30T16:25:32+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/unrecognizable-scientist-MDF3BQY.jpg https://www.mel-montmedical.com/melmont_validations/human-papillomavirus-dna-and-e6-e7-mrna-status-in-relation-to-survival-of-patients-treated-for-cervical-squamous-cell-carcinoma/ 2020-12-30T16:20:04+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/assessment-of-hpv-mrna-test-to-predict-recurrent-disease-in-patients-previously-treated-for-cin-2-3/ 2020-12-30T16:08:25+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/unrecognizable-scientist-MDF3BQY.jpg https://www.mel-montmedical.com/melmont_validations/comparison-3-commercial-assays-high-risk-hpv/ 2020-12-29T21:51:41+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/scientist-hands-with-microscope-PUCV3KY.jpg https://www.mel-montmedical.com/melmont_validations/analytical-performance-of-rna-isolated-from-bd-surepathtm-cervical-cytology-specimens-by-the-pretecttm-hpv-proofer-assay/ 2020-12-29T21:49:31+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/detecting-hpv-e6-e7/ 2020-12-18T20:48:29+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/unrecognizable-scientist-MDF3BQY.jpg https://www.mel-montmedical.com/melmont_validations/hpv-e6-e7-mrna-test/ 2020-12-18T19:55:14+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/nominated_t20_gowJ97.jpg https://www.mel-montmedical.com/melmont_validations/comparing-6-hpv-tests-screening-population/ 2020-12-18T19:51:47+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/78080409_m.jpg https://www.mel-montmedical.com/melmont_validations/assessment-hpv-mrna/ 2020-12-18T19:47:29+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Image-1-RD.jpg https://www.mel-montmedical.com/melmont_validations/human-papillomavirus-dna-rna/ 2020-12-18T19:41:44+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/nominated_t20_gowJ97.jpg https://www.mel-montmedical.com/melmont_validations/comparison-oncogenic-hpv/ 2020-12-18T19:17:28+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/sensitivity-specificity-and-clinical-value-hpv/ 2020-12-18T19:14:35+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/scientist-in-lab-P96ATWK.jpg https://www.mel-montmedical.com/melmont_validations/hpv-genotype-distribution-cervical-cancer/ 2020-12-18T18:49:34+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Image-1-RD.jpg https://www.mel-montmedical.com/melmont_validations/massarray-spectrometry-hpv/ 2020-12-18T18:42:57+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/human-papillomavirus-dna/ 2020-12-18T18:32:57+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Mision-Imagen.jpg https://www.mel-montmedical.com/melmont_validations/expression-of-e6-e7-mrna/ 2020-12-18T18:32:16+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/09/scientist-hands-with-microscope-PUCV3KY.jpg https://www.mel-montmedical.com/melmont_validations/performance-proex-and-pretect/ 2020-12-18T18:22:13+00:00 https://www.mel-montmedical.com/wp-content/uploads/2020/11/Image-1-RD.jpg